Alle Studien
RekrutierungPhase IIIInterventionell

A study comparing intermittent with continuous treatment with BTK inhibitors in chronic lymphocytic leukaemia (CLL)

Targeted tablets called BTK inhibitors (ibrutinib and acalabrutinib) are very effective at keeping chronic lymphocytic leukaemia (CLL) under control. Usually, patients must take these tablets every day for many years. Over time, this can lead to bothersome side effects, and the leukaemia cells may become resistant to the medication. The STATIC trial, run by the University of Leeds, is testing whether it is safe to pause treatment when a person's leukaemia is in a stable, deep remission. Half of the participants will stay on their daily medication, while the other half will pause their tablets and only restart if the leukaemia shows early signs of returning. The team hopes this will reduce side effects, lower the risk of drug resistance, and improve quality of life, without letting the leukaemia get worse.

Auf einen Blick

Status
Rekrutierung
Phase
Phase III
Sponsor
Universität Leeds
Einschreibeziel
830
Starten
13. Okt 2022
Geschätzte Fertigstellung
01 Sep 2028

Worum geht es in dieser Studie?

Chronic lymphocytic leukaemia (CLL) is a slow-growing type of blood cancer that affects white blood cells. In recent years, newer targeted medicines called BTK inhibitors—including ibrutinib and acalabrutinib—have transformed treatment. Rather than wiping out cells like traditional chemotherapy, these daily tablets specifically block proteins that help leukaemia cells grow and survive.

At the moment, standard care involves taking these tablets every single day for years, often indefinitely. While they work well, taking them continuously can cause long-term side effects such as joint aches, fatigue, high blood pressure, or bleeding issues. There is also a risk that the leukaemia can eventually adapt and become resistant to the drug.

The STATIC trial aims to find out if taking planned breaks from treatment is just as safe and effective as taking tablets every day. Doctors want to see if pausing the medicine once the leukaemia is well controlled gives the body a rest, cuts down on side effects, improves emotional wellbeing, and prevents the cancer from becoming resistant.

This is a Phase III clinical trial involving over 800 patients across the UK. By comparing people who take continuous treatment with those who take planned breaks, the study will provide clear evidence on whether treatment guidelines can be safely changed for future NHS patients.

Wichtige Erkenntnisse

  • The STATIC trial compares taking daily CLL tablets non-stop against taking planned treatment breaks.
  • Breaks are only taken when the leukaemia is in a deep, stable remission.
  • The study tests whether breaks reduce side effects, improve wellbeing, and stop drugs from losing effectiveness.
  • Participants are monitored very closely so medication can be restarted promptly if needed.
  • Taking part is completely voluntary and you can leave the study at any time.

Wer könnte berechtigt sein?

This trial is open to adults aged 18 and over who have chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). You must be reasonably well in your everyday life, meaning you can carry out most daily activities, and your liver function tests need to be within a safe range.

To join the main comparison group, you must already be taking ibrutinib or acalabrutinib (either as your first treatment or a later treatment) and your cancer must currently be in a good remission. This means your blood counts are steady, and your doctor cannot feel any swollen lymph glands or an enlarged spleen. People finishing up other specific CLL trials, such as the FLAIR or IcICLLe studies, may also be able to join.

A separate group in the trial is designed for people who need to stay on ibrutinib because their leukaemia is showing early signs of returning after previous clinical trials. Because these medicines can harm an unborn baby, you will also need to agree to use reliable contraception while taking the tablets.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I am aged 18 or over.
  2. I have been diagnosed with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
  3. I am currently taking ibrutinib or acalabrutinib.
  4. My leukaemia is currently well controlled (in remission), with steady blood counts and no swollen lymph nodes.
  5. I am generally active and able to look after myself day-to-day.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join the main part of the STATIC trial, a computer will place you at random into one of two groups. One group will carry on taking their usual daily tablets without a break. The other group will stop taking their tablets while their leukaemia remains in remission. If tests show the cancer is starting to wake up, treatment will be restarted right away.

No matter which group you are in, your care team will monitor you very closely with regular outpatient hospital visits. At these appointments, you will have routine blood tests, physical examinations to check for swollen glands, and check-ups to review any side effects. You will also be asked to complete short questionnaires about how you are feeling emotionally and physically. The study is planned to follow patients over several years, running until roughly 2031, so doctors can see how both approaches compare in the long run.

Potenzielle Risiken und Vorteile

Taking part may give you the chance to take a break from daily tablets, which could reduce unwanted side effects and improve your day-to-day life, though this cannot be guaranteed. The biggest concern for many people taking a break is the worry that their cancer might return; however, the trial monitors you very closely so treatment can be restarted at the earliest sign of change. For those who continue daily treatment, side effects may carry on, but your team can often manage these by adjusting your dose. Joining the study is completely voluntary, and you can withdraw at any time without your regular NHS care being affected.

Standorte (55)

  • St James's Hospital
    Ungefähr
    Leeds, England
  • Aberdeen Royal Infirmary
    Ungefähr
    Aberdeen, Scotland
  • Good Hope Hospital
    Ungefähr
    Sutton Coldfield, England
  • Heartlands Hospital
    Ungefähr
    Birmingham, England
  • Victoria Hospital (blackpool)
    Ungefähr
    Blackpool, England
  • Bradford Royal Infirmary
    Unbestätigt
    Bradford, England
  • Castle Hill Krankenhaus
    Unbestätigt
    Cottingham, England
  • Christie Hospital
    Unbestätigt
    Manchester, England
  • Churchill Krankenhaus
    Unbestätigt
    Oxford, England
  • Clatterbridge Krankenhaus
    Unbestätigt
    Wirral, England
  • Derriford Hospital
    Unbestätigt
    Plymouth, England
  • Grantham and District Hospital
    Unbestätigt
    Grantham, England

Häufige Fragen

Can I choose whether I take a break from my medication?

No. In the randomised trial, a computer decides by chance whether you stay on daily treatment or take planned breaks. This is the fairest way to compare the two approaches.

What happens if my leukaemia comes back during a treatment break?

You will have regular blood tests and checks. If the leukaemia shows early signs of returning, your doctor will restart your targeted tablets immediately to bring it back under control.

Will I have to pay for the trial medication?

No. All study medications and extra trial-related tests are provided free of charge through the NHS and trial partners.

Do I still need to use contraception during treatment breaks?

You must use reliable contraception while taking the tablets, but trial rules do not require you to follow the strict trial contraception plan during planned breaks. Your study doctor will explain what is safest for your situation.

Kann ich die Studie verlassen, wenn ich meine Meinung ändere?

Yes. You are free to leave the trial at any point. Deciding to withdraw will not affect the quality of your regular NHS medical care or your relationship with your doctor.

Wie Sie mehr erfahren können

Sue Bell

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A study comparing intermittent with continuous treatment wit… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.